Description

Cagrilintide Peptide High-Purity Long-Acting Amylin Analog

Cagrilintide peptide is an investigational, long-acting acylated amylin analog under development for weight management and metabolic disorder research. As a non-selective amylin receptor (AMYR) and calcitonin receptor (CTR) agonist, this cagrilintide peptide plays a crucial role in regulating appetite and body weight. It has shown significant promise in clinical trials, both as a monotherapy and in combination with GLP-1 agonists like semaglutide, for achieving substantial weight loss. Available as a lyophilized powder with high purity, cagrilintide is a key research tool for studying obesity and related metabolic pathways.

Key Research Findings and Clinical Data

Mechanism of Action
Cagrilintide is a synthetic analog of amylin, a hormone co-secreted with insulin from pancreatic β-cells. It works by activating AMYR and CTR receptors, which induces satiety, slows gastric emptying, and reduces post-prandial glucagon levels. This unique mechanism provides an alternative approach to currently approved GLP-1-based treatments for weight loss. Recent structural studies reveal that cagrilintide peptide binds to these receptors in a way that induces distinct conformational dynamics, contributing to its clinical efficacy.

Clinical Efficacy: REDEFINE 1 Trial
The Phase 3 REDEFINE 1 trial evaluated cagrilintide as a monotherapy. Results showed an average weight reduction of 11.8% after 68 weeks, compared to 2.3% with placebo. This study included 3,417 participants and was published in the New England Journal of Medicine, underscoring the significant and clinically relevant body-weight reductions achievable with cagrilintide .

Combination Therapy: CagriSema
Cagrilintide peptide has been studied extensively in combination with semaglutide (CagriSema). This combination has demonstrated superior weight loss compared to either component alone. In the REIMAGINE 2 trial for adults with type 2 diabetes, CagriSema achieved a weight loss of up to 14.2% and reduced HbA1c by 1.91%-points. In a head-to-head trial (REDEFINE 4) against tirzepatide, CagriSema achieved a 23% weight loss after 84 weeks of treatment. This combination strategy highlights the synergistic potential of cagrilintide with GLP-1 receptor agonists.

Safety and Tolerability
Across clinical trials, cagrilintide peptide was well-tolerated. The most common side effects were mild-to-moderate gastrointestinal events, including nausea, vomiting, and diarrhea. Discontinuation rates due to adverse events were low, with only 1% of patients stopping treatment due to nausea in the REDEFINE 1 trial. This favorable tolerability profile makes it a promising candidate for long-term weight management.

Product Details & Research Specifications

• Product Name: Cagrilintide

• CAS Number: 1415456-99-3

• Molecular Formula: C194H312N54O59S2

• Molecular Weight: 4409.01 g/mol

• Purity: >98.0% (HPLC)

• Appearance: White to off-white powder

• Form: Lyophilized (freeze-dried) powder

• Storage: Store at -20°C for long-term storage. For short-term use, 2-8°C is acceptable. Protect from light and moisture.

• Solubility: Soluble in sterile water or buffer for research use.

• Research Use Only: This product is intended strictly for laboratory research and development. It is not for human or animal consumption, nor is it for diagnostic or therapeutic use.

Frequently Asked Questions (FAQ)

What is Cagrilintide peptide used for in research?
Cagrilintide peptide is primarily used in research to study its effects on weight management and metabolic disorders. As a long-acting amylin analog, it helps researchers understand appetite regulation, gastric emptying, and energy homeostasis. It is also a key component in studies investigating combination therapies for obesity and type 2 diabetes.

How does Cagrilintide differ from GLP-1 agonists like semaglutide?
While both classes of drugs induce weight loss, they work through different mechanisms. GLP-1 agonists like semaglutide primarily act on GLP-1 receptors to stimulate insulin secretion and suppress appetite. Cagrilintide peptide, however, is an amylin analog that activates AMYR and CTR receptors, inducing satiety and slowing gastric emptying. This distinct action allows for potential synergistic effects when combined with GLP-1 agonists, as seen in studies of CagriSema.

What are the main findings from clinical trials of Cagrilintide?
Key findings from the Phase 3 REDEFINE 1 trial show that cagrilintide monotherapy led to an average 11.8% weight loss over 68 weeks. When combined with semaglutide in the REIMAGINE 2 trial, the combination achieved up to 14.2% weight loss and significant HbA1c reduction. These results highlight its potential as an effective treatment for obesity and related metabolic conditions.

What are the common side effects of Cagrilintide in research models?
In clinical studies, the most frequently reported adverse events are gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation. These side effects are generally mild to moderate and transient. The discontinuation rate due to these events was low, at around 1%, suggesting good tolerability.

How should Cagrilintide peptide be stored for optimal stability?
For research purposes, cagrilintide powder should be stored in a freezer at or below -20°C. Upon reconstitution with a suitable solvent, the solution should be aliquoted and stored at -20°C to prevent freeze-thaw degradation. It is crucial to protect the product from light and moisture to maintain its integrity.

Is Cagrilintide available for purchase?
Yes, cagrilintide peptide is available for purchase from various research chemical suppliers. However, it is strictly sold for laboratory research and development purposes and is not intended for human use. Our product is sourced from reputable manufacturers and undergoes rigorous quality control, including HPLC and Mass Spectrometry (MS), to ensure high purity and reliability.